Adam J Olszewski
Overview
Explore the profile of Adam J Olszewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davids M, Ryan C, Lampson B, Ren Y, Tyekucheva S, Fernandes S, et al.
J Clin Oncol
. 2024 Dec;
43(7):788-799.
PMID: 39645236
Purpose: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type ; however,...
2.
Grover N, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzman A, et al.
Blood Cancer J
. 2024 Oct;
14(1):182.
PMID: 39424808
Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( > 20%) as well as increased numbers of large B cells (LC). However, there...
3.
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2024 Aug;
8(20):5355-5364.
PMID: 39189932
Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement,...
4.
Mirza F, Olszewski A, Pelcovits A, DiMarco C, Firoz E
JAAD Case Rep
. 2024 May;
48:103-107.
PMID: 38813064
No abstract available.
5.
Bhansali R, Ellin F, Relander T, Cao M, Li W, Long Q, et al.
Blood Adv
. 2024 May;
8(13):3507-3518.
PMID: 38739715
Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS...
6.
Baird C, Wulff-Burchfield E, Egan P, Hugar L, Vyas A, Trikalinos N, et al.
J Geriatr Oncol
. 2024 Apr;
15(5):101774.
PMID: 38676975
Introduction: High-intensity end-of-life (EoL) care can be burdensome for patients, caregivers, and health systems and does not confer any meaningful clinical benefit. Yet, there are significant knowledge gaps regarding the...
7.
Milrod C, Kim K, Raker C, Ollila T, Olszewski A, Pelcovits A
Br J Haematol
. 2024 Apr;
204(6):2237-2241.
PMID: 38571449
Although progression-free survival (PFS) is a commonly used surrogate end-point for clinical trials of follicular lymphoma (FL), no analyses have evaluated the strength of surrogacy for PFS with overall survival...
8.
9.
Epperla N, Zhao Q, Moyo T, Watkins M, Tavakkoli M, Bello C, et al.
Blood Adv
. 2023 Dec;
8(3):549-552.
PMID: 38091577
No abstract available.
10.
Budde L, Olszewski A, Assouline S, Lossos I, Diefenbach C, Kamdar M, et al.
Nat Med
. 2023 Dec;
30(1):229-239.
PMID: 38072960
Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet need. Here we report the primary analysis of a phase 1b/2 trial of outpatient mosunetuzumab (a CD20xCD3 T-cell-engaging...